英国剑桥生物益生菌(剑桥团队研发出选定益生菌的新方法)

Introduction

Probiotics are beneficial bacteria that when consumed in adequate quantities, confer health benefits to the host. Probiotics have gained immense popularity in recent years as their benefits in maintaining gut health and improving immune function have been well-established. The market for probiotic products has expanded exponentially with a projected value of $72 billion by 2024. However, researchers have raised concerns about the lack of standardized testing protocols and strain-specific efficacy of probiotics. The UK-based Cambridge team has recently developed a novel approach to select probiotic strains based on their ability to survive and thrive in the gut environment.

The Cambridge Approach

The Cambridge team initially screened over 3,000 bacterial strains sourced from the human gut, food, and other environments. The team used a simulated gut model to mimic the harsh gastrointestinal conditions of the human gut to select for strains that exhibit robust growth and survival rates. The model also evaluated the ability of the strains to modulate the immune system, reduce inflammation, and promote gut barrier function. The team identified a shortlist of promising strains that demonstrated excellent survival rates, immune-modulatory properties, and niche-specific properties.

Strain Characterization and Selection

The shortlisted strains were subjected to in-depth characterization using culture-dependent and independent methods to confirm their identity, taxonomy, and genetic stability. The strains were also tested for a range of phenotypic characteristics such as antibiotic resistance, acid and bile tolerance, exopolysaccharide production, and adhesion to epithelial cells. The team narrowed down the list to five strains that exhibited remarkable growth and survival rates, excellent immune-modulatory properties, and high stability under varying conditions.

Clinical Trials

The selected strains were tested in vitro for their ability to antagonize pathogenic bacteria such as Salmonella, Escherichia coli, and Clostridium difficile. The strains were also evaluated for their potential to modulate the gut microbiota composition in vivo using a mouse model. The team conducted a placebo-controlled double-blind clinical trial involving volunteers with gastrointestinal disorders. The trial showed that the administration of the probiotic mixture resulted in significant improvements in gut health, immune function, and quality of life.

Conclusion

The Cambridge team has developed a pioneering approach to select probiotic strains based on their ability to survive and thrive in a simulated gut model. The selection process involved a multi-faceted approach that evaluated the strain-specific properties, niche-specific properties, and their ability to modulate the immune system. The selected strains were shown to confer significant health benefits in preclinical and clinical trials. This innovative approach to select probiotic strains has the potential to revolutionize the probiotic product market and provide consumers with more effective and reliable probiotics.